ST. Louis Mo - April 28, 2021
M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today a poster presentation on mucolipidosis type II at the American Society of Gene & Cell Therapy’s (ASGCT) 24thAnnual Meeting: May 11-14, 2021.
The details of the virtual presentation are as follows:
- Abstract Title: “Pilot Study of M002, a Novel AAV9-Mediated Gene Therapy for Treatment of Mucolipidosis Type II (MLII) Using a Modified Phosphotransferase (S1S3)”
- Session Date/Time: Tuesday May 11, 2021 8:00 – 10:00 a.m. ET
- Session Title: AAV Vectors – Preclinical and Proof-of-Concept Studies
- Room: Digital Gallery
- Final abstract number: 373
About M6P Therapeutics
M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted enzyme replacement and gene therapies for lysosomal storage disorders (LSDs). M6P Therapeutics’ proprietary S1S3 co-expression platform has the unique ability to enhance phosphorylation of lysosomal enzymes for both enzyme replacement and gene therapies, leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases. M6P Therapeutics’ team, proven in rare diseases drug development and commercialization, is dedicated to fulfilling the promise of enzyme replacement and gene therapies by harnessing the power of protein phosphorylation using its S1S3 co-expression platform. M6P Therapeutics’ mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community. For more information, please visit: www.m6ptherapeutics.com.